

BOX AF

AF/1646

RESPONSE UNDER 37 CFR 1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1646

June 17, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: 09/901,556

Applicant : Hötten et al. Filed : September 24, 1999

Filed : Septe TC/A.U. : 1646

Examiner : P. Mertz

Docket No. : 2923-286

Customer No.: 06449 Confirmation No.: 3191

AMENDMENT UNDER 37 CFR 1.116

Commissioner of Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In response to the Office action of April 15, 2004, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 9 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-19 (canceled)

Claim 20 (currently amended): An antibody or antibody fragment which specifically binds to a protein of the TGF-B family wherein said antibody or antibody fragment binds to a part of the protein encoded by a DNA comprising a nucleotide sequence selected from the following group:

- (a) the nucleotide sequence as shown in SEQ ID NO:1,
- (b) a nucleotide sequence which is degenerate as a result of the genetic code to the nucleotide sequence of (a), and
- (c) fragments of (a) or (b) which encode a protein which has essentially retains the same cartilage or bone inducing activities as of a mature protein encoded by the nucleotide sequence of SEQ ID NO:1.

Claim 21 (previously presented): The antibody according to claim 20, wherein said antibody is a monoclonal antibody.

Claim 22 (currently amended): An antibody or antibody fragment according to claim 20, which specifically binds to a protein of the TGF-B family wherein the